Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | MET | P08581 | 9/20 | 0.35 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 3/20 | 0.33 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13275278 | 0.92 | MET (0.39) | PPARGPPARAMETTAS2R8IGF1R | |
| SCHEMBL2265508 | 0.92 | MET (0.34) | PPARGPPARAMETIGF1RHSD17B13 | |
| SCHEMBL2222454 | 0.90 | MET (0.35) | PPARGPPARAMETIGF1RHSD17B13 | |
| SCHEMBL12517938 | 0.90 | ALKBH1 (0.39) | PPARGPPARA | |
| SCHEMBL2268190 | 0.90 | PPARG (0.37) | PPARGPPARAMETHSD17B13 | |
| SCHEMBL2228967 | 0.89 | MCHR1 (0.32) | PPARGPPARAMETIGF1RHSD17B13 | |
| SCHEMBL2263526 | 0.89 | IGF1R (0.34) | PPARGPPARAMETTAS2R8IGF1R | |
| SCHEMBL13449337 | 0.89 | HSD17B13 (0.39) | PPARGPPARAMETTAS2R8IGF1R | |
| SCHEMBL2218909 | 0.88 | MET (0.33) | PPARGPPARAMETIGF1RHSD17B13 | |
| SCHEMBL13275026 | 0.88 | SYK (0.33) | PPARGPPARAMETIGF1RHSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | claimed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | PPARG 2354/4885PPARA 3069/4885MET 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.